Developmental regulation of P‐glycoprotein activity within thymocytes results in increased anti‐HIV protease inhibitor activity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Leukocyte Biology

• Publication date

  2011-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1189/jlb.0111-009PMID 21504949PMCID PMC3409632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir

  2009cited by this paper
• Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children

  2008cited by this paper
• Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.

  2008cited by this paper
• Antiretroviral therapy corrects HIV-1-induced expansion of CD8+ CD45RA+ CD2-) CD11a(bright) activated T cells.

  2008cited by this paper
• The role of the thymus in HIV infection: a 10 year perspective

  2008influential reference
• Phylodynamics of HIV-1 in Lymphoid and Non-Lymphoid Tissues Reveals a Central Role for the Thymus in Emergence of CXCR4-Using Quasispecies

  2007cited by this paper
• Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice

  2007cited by this paper
• Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

  2007cited by this paper
• Thymic microenvironments for T cell differentiation and selection

  2006cited by this paper
• Recent Progress in Understanding the Mechanism of P-Glycoprotein-mediated Drug Efflux

  2005cited by this paper
• Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells

  2005cited by this paper
• Functional Correlation of P-Glycoprotein Expression and Genotype with Expression of the Human Immunodeficiency Virus Type 1 Coreceptor CXCR4

  2004cited by this paper
• P Glycoprotein in Human Immunodeficiency Virus Type 1 Infection and Therapy

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• P-glycoprotein and HIV.

  2002cited by this paper
• Generation of HIV latency during thymopoiesis

  2001cited by this paper
• HIV‐Protease Inhibitors Contribute to P‐Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV‐Positive Patients Receiving HAART

  2001influential reference
• Impaired replication of protease inhibitor-resistant HIV-1 in human thymus

  2001cited by this paper
• Evaluation of T cell receptor gene rearrangement excision circles after antiretroviral therapy in children infected with human immunodeficiency virus.

  2001cited by this paper
• P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

  2001cited by this paper
• Effect of ABC transporters on HIV‐1 infection: inhibition of virus production by the MDR1 transporter

  2000cited by this paper
• Multiple physiological functions for multidrug transporter P-glycoprotein?

  2000cited by this paper
• Effect of HIV on thymic function before and after antiretroviral therapy in children.

  2000cited by this paper
• Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection.

  2000cited by this paper
• P-Glycoprotein and Bioavailability-Implication of Polymorphism

  2000cited by this paper
• Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors.

  2000cited by this paper
• Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors

  2000cited by this paper
• Functional Reconstitution of Thymopoiesis after Human Immunodeficiency Virus Infection

  2000cited by this paper
• HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

  1999cited by this paper
• Interactions of HIV protease inhibitors with ATP-dependent drug export proteins.

  1999cited by this paper
• Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages.

  1999cited by this paper
• Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children.

  1999cited by this paper
• Differential activity of P‐glycoprotein in normal blood lymphocyte subsets

  1998cited by this paper
• Changes in thymic function with age and during the treatment of HIV infection

  1998cited by this paper
• CXCR4 and CCR5 expression delineates targets for HIV-1 disruption of T cell differentiation.

  1998cited by this paper
• HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

  1998cited by this paper
• CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection.

  1998cited by this paper
• Differential Tropism and Replication Kinetics of Human Immunodeficiency Virus Type 1 Isolates in Thymocytes: Coreceptor Expression Allows Viral Entry, but Productive Infection of Distinct Subsets Is Determined at the Postentry Level

  1998cited by this paper
• Downregulation of CD1 Marks Acquisition of Functional Maturation of Human Thymocytes and Defines a Control Point in Late Stages of Human T Cell Development

  1997cited by this paper
• Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV‐infected patients

  1997cited by this paper
• Saquinavir-mediated inhibition of human immunodeficiency virus (HIV) infection in SCID mice implanted with human fetal thymus and liver tissue: an in vivo model for evaluating the effect of drug therapy on HIV infection in lymphoid tissues

  1997cited by this paper
• CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus

  1997cited by this paper
• Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV‐infected patients

  1997cited by this paper
• Early progression of disease in HIV-infected infants with thymus dysfunction.

  1996cited by this paper
• Differential tropism of HIV‐1 isolates for distinct thymocyte subsets in vitro

  1996cited by this paper
• Multidrug transporter p‐glycoprotein 170 as a differentiation antigen on normal human lymphocytes and thymocytes: Modulation with differentiation stage and during aging

  1995cited by this paper
• Structure-activity relationship of verapamil analogs and reversal of multidrug resistance.

  1995cited by this paper
• P-glycoprotein expression and function in circulating blood cells from normal volunteers.

  1994cited by this paper
• The SCID-hu mouse as a model for HIV-1 infection

  1993cited by this paper
• Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes.

  1992cited by this paper
• Preferential expression and activity of multidrug resistance gene 1 product (P-glycoprotein), a functionally active efflux pump, in human CD8 + T cells: A role in cytotoxic effector function

  1992cited by this paper
• Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype.

  1992cited by this paper
• Lymphocytes

  1991cited by this paper
• Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Analysis with 3 monoclonal antibodies recognizing different epitopes of the P-glycoprotein molecule.

  1990cited by this paper
• Distribution of multidrug resistance-associated P-glycoprotein in normal and neoplastic human tissue

  1990cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper

• Pharmacology of HIV Cure: Site of Action

  2021cites this paper
• P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load

  2016cites this paper
• Nature and uses of fluorescent dyes for drug transporter studies

  2015cites this paper
• Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.

  2015cites this paper
• Drug transporters in tissues and cells relevant to sexual transmission of HIV: Implications for drug delivery.

  2015cites this paper
• P-Glycoprotein and Drug Resistance in Systemic Autoimmune Diseases

  2014cites this paper
• Editorial: Developmental regulation of P‐glycoprotein and HIV therapy: spare the thymus but spoil the child?

  2011cites this paper